Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 8/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30639701 | 1.00 | LPL (0.37) | LPLLIPGCSF1RIRAK4ROCK1 | |
| SCHEMBL20356417 | 0.88 | CSF1R (0.37) | LPLLIPGCSF1RIRAK4ROCK1 | |
| SCHEMBL29592995 | 0.88 | CSF1R (0.37) | LPLLIPGCSF1RIRAK4ROCK1 | |
| SCHEMBL782545 | 0.81 | DDB1 (0.42) | LPLLIPGCSF1RIRAK4CA1 | |
| SCHEMBL16362028 | 0.78 | JAK2 (0.32) | — | |
| SCHEMBL16475230 | 0.77 | LPL (0.40) | LPLLIPGCSF1RIDO1 | |
| SCHEMBL30639699 | 0.77 | LPL (0.40) | LPLLIPGCSF1RIDO1 | |
| SCHEMBL29455590 | 0.77 | CSF1R (0.37) | LPLLIPGCSF1RIRAK4ROCK1 | |
| SCHEMBL782308 | 0.75 | LPL (0.41) | LPLLIPGIDO1 | |
| SCHEMBL29038853 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | CEREVANCE INC (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209368-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | Cerevance, Inc. (US) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282728-A1 | NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR | GPR55, GPR68, GPR65 | LPL 2320/4885LIPG 1956/4885CSF1R 1088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.